Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosis

This publication has 15 references indexed in Scilit:

• A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
  New England Journal of Medicine, 1999
• Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial
  Vascular Medicine, 1998
• Interrelation of Hyperhomocyst(e)inemia, Factor V Leiden, and Risk of Future Venous Thromboembolism
  Circulation, 1997
• The Risk of Recurrent Venous Thromboembolism in Patients with an Arg⁵⁰⁶→Gln Mutation in the Gene for Factor V (Factor V Leiden)
  New England Journal of Medicine, 1997
• The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
  New England Journal of Medicine, 1997
• Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism
  Circulation, 1995
• A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism
  New England Journal of Medicine, 1995
• Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
  New England Journal of Medicine, 1995
• Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
  The Lancet, 1993
• Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
  The Lancet, 1992